home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480588.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
3KB
|
41 lines
Document 0588
DOCN M9480588
TI Structure-based design of symmetric inhibitors of HIV-1 protease.
DT 9410
AU Erickson J; Kempf D; Structural Biochemistry Program, Frederick
Biomedical; Supercomputing Center, National Cancer Institute, Frederick;
Cancer Research and Development Center, Maryland.
SO Arch Virol Suppl. 1994;9:19-29. Unique Identifier : AIDSLINE
MED/94305396
AB HIV-1, the causative agent of AIDS, encodes a protease that processes
the viral polyproteins into the structural proteins and replicative
enzymes found in mature virions. Protease activity has been shown to be
essential for the proper assembly and maturation of fully infectious
HIV-1. Thus, the HIV-1 protease (HIV PR) has become an important target
for the design of antiviral agents for AIDS. Analysis of the
three-dimensional structures of related aspartic proteinases, and later
of Rous sarcoma virus protease, indicated that the active site and
extended substrate binding cleft exhibits two-fold (C2) symmetry at the
atomic level. We therefore set out to test whether compounds that
contained a C2 axis of symmetry, and that were structurally
complementary to the active site region, could be potent and selective
inhibitors of HIV PR. Two novel classes of C2 or pseudo-C2 symmetric
inhibitors were designed, synthesized and shown to display potent
inhibitory activity towards HIV PR, and one of these, A-77003, recently
entered clinical trials. The structure of the complex with A-74704 was
solved using X-ray crystallographic methods and revealed a highly
symmetric mode of binding, confirming our initial design principles.
These studies demonstrate that relatively simple symmetry considerations
can give rise to novel compound designs, allowing access to imaginative
new templates for synthesis that can be translated into experimental
therapeutic agents.
DE *Drug Design HIV Protease/*DRUG EFFECTS HIV Protease
Inhibitors/*PHARMACOLOGY HIV-1/*DRUG EFFECTS/GROWTH & DEVELOPMENT
Models, Molecular Molecular Conformation Structure-Activity
Relationship Sugar Alcohols/*CHEMISTRY Valine/*ANALOGS &
DERIVATIVES/CHEMISTRY JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).